5-Methoxy-6-methyl-2-aminoindane (MMAI) CAS # 132980-16-6

5-Methoxy-6-methyl-2-aminoindane (MMAI) CAS # 132980-16-6


Share this product


5-Methoxy-6-methyl-2-aminoindane (MMAI), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogen effects in humans. It has been sold as a designer drug and research chemical online since 2010.

MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline, and as a result it has been suggested that SSRAs like MMAI and 4-MTA could be developed as novel antidepressants with a faster onset of therapeutic action and superior efficacy to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs).


There are no reviews yet.

Be the first to review “5-Methoxy-6-methyl-2-aminoindane (MMAI) CAS # 132980-16-6”

Your email address will not be published.